Clinical trials: Type II Diabetic Patients With Nephropathy
Diabetic Nephropathy
Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
1. The primary objective of this study was： in patients with type 2 diabetes and microalbuminuria who have been receiving stable treatment of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) for…
- Trial name
- NCT02035891
- Testing
- colchicine 0.5mg/d
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chongqing Medical University
Essential Hypertension, Type 2 Diabetes
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups…
- Conditions
- Essential Hypertension, Type 2 Diabetes, Nephropathy
- Trial name
- Hyper-Save (NCT06501651)
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Sichuan Academy of Medical Sciences
Type 2 Diabetes, Diabetic Nephropathy
Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.
Hypertension is highly prevalent in type 2 diabetic patients (NIDDM) with nephropathy, and is the single most important determinant of the rate of renal function loss.
- Conditions
- Type 2 Diabetes, Diabetic Nephropathy, Hypertension, Sleep Apnea
- Trial name
- SAS (NCT01875341)
- Testing
- NCPAP; Nasal continuous positive airway pressure., NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Diabetic Nephropathies, Diabetes Mellitus, Type II
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
Background The relationship between long-term heavy lead exposure and chronic interstitial nephropathy is well recognized in the previous literatures.
- Trial name
- NCT00237952
- Testing
- EDTA chelating agents
- Where
- 2 sites in China
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Diabetic Kidney Disease, Obesity
Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
1. Comparison between the 4 groups of metabolic phenotypes of obesity as regard the presence and frequency of DKD 2. Relation between DKD , obesity (BMI) and metabolic risk factors in patients with type 2 DM
- Conditions
- Diabetic Kidney Disease, Obesity, Metabolic Syndrome, Diabetes Mellitus, Type 2
- Trial name
- NCT06591104
- Testing
- 24 hour urinary protein
- Volunteers
- 71 people
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy Type 2
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
- Trial name
- NCT06068439
- Testing
- Acetylsalicylic Acid
- Volunteers
- 355 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Diabetic Kidney Disease, Chronic Kidney Diseases
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- NCT05198284
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathy, Chronic Kidney Disease
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
Diabetes mellitus (DM) is a growing disease and it is a public health concern, and projections of its future effect are alarming. About one third of those affected will develop diabetic nephropathy at 20 years after diagnosis.
- Trial name
- Myridian (NCT01566006)
- Testing
- Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- The Nazareth Hospital, Israel
Diabetic Nephropathy, Dyslipidemia
The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus
The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.
- Trial name
- NCT07476248
- Volunteers
- 84 people
- Sponsor
- Assiut University
Chronic Kidney Diseases, Diabetic Kidney Disease
Real World Evidence Clinical Utility Study of KidneyIntelX
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
- Trial name
- NCT04802395
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetic Kidney Disease, Diabetes Mellitus, Type 2
EMPRA (EMPagliflozin and RAs in Kidney Disease)
This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone.
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- EMPRA (NCT03078101)
- Testing
- Empagliflozin 10 MG [Jardiance]
- Where
- Austria
- Volunteers
- 51 people
- Sponsor
- Medical University of Vienna
Diabetes Mellitus, Coronary Artery Bypass
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary…
- Conditions
- Diabetes Mellitus, Coronary Artery Bypass, Remote Ischaemic Conditioning
- Trial name
- NCT06977230
- Testing
- Remote Ischemic Preconditioning
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Muğla Sıtkı Koçman University
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)